Green Alpha Advisors LLC grew its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 138.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 432,325 shares of the company's stock after buying an additional 251,271 shares during the period. Green Alpha Advisors LLC owned 0.46% of Caribou Biosciences worth $395,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in CRBU. Centric Wealth Management bought a new position in Caribou Biosciences in the 4th quarter worth approximately $27,000. Russell Investments Group Ltd. boosted its holdings in Caribou Biosciences by 859.0% in the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock worth $38,000 after buying an additional 21,416 shares during the period. MetLife Investment Management LLC boosted its holdings in Caribou Biosciences by 60.0% in the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock worth $39,000 after buying an additional 9,148 shares during the period. Diametric Capital LP bought a new position in Caribou Biosciences in the 4th quarter worth approximately $42,000. Finally, US Bancorp DE boosted its holdings in Caribou Biosciences by 3,524.2% in the 4th quarter. US Bancorp DE now owns 27,218 shares of the company's stock worth $43,000 after buying an additional 26,467 shares during the period. Hedge funds and other institutional investors own 77.51% of the company's stock.
Caribou Biosciences Price Performance
NASDAQ:CRBU traded down $0.02 during trading hours on Thursday, hitting $1.11. The stock had a trading volume of 301,550 shares, compared to its average volume of 1,410,336. The company has a 50 day simple moving average of $0.88 and a two-hundred day simple moving average of $1.31. Caribou Biosciences, Inc. has a one year low of $0.66 and a one year high of $3.00. The firm has a market capitalization of $103.15 million, a price-to-earnings ratio of -0.67 and a beta of 2.44.
Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. Equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.
Get Our Latest Analysis on Caribou Biosciences
Caribou Biosciences Profile
(
Free Report)
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Read More

Before you consider Caribou Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caribou Biosciences wasn't on the list.
While Caribou Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.